missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human MSC (aa 3-45) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (74%), Rat (74%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-84571 (PA5-84571. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
MyoD-E or musculin-E heterodimers bind avidly to consensus E box motifs, which are functionally important elements in the promoter regions of many musclespecific terminal differentiation genes. MyoD complexes potently induce transcriptional activation, while musculin complexes bind adjacent to MyoD DNA-binding regions to represses MyoD activity, which then results in the delayed expression of muscle-specific genes. Musculin is highly expressed in undifferentiated and proliferating myoblasts in culture, and its expression is down regulated during myogenesis and at the onset of terminal differentiation.
Specifications
Specifications
| Accession Number | O60682 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 9242 |
| Name | Human MSC (aa 3-45) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | ABF1; ABF-1; Activated B-cell factor 1; activated B-cell factor 1, homolog of mouse musculin; activated B-cell factor-1; bHLHa22; Class A basic helix-loop-helix protein 22; Msc; Musculin; myogenic repressor; Myor |
| Common Name | MSC |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction